The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index, and 1 are not checked yet.
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
Open accessAbstract
OBJECTIVE: In retrospective studies, liver stiffness (LS) by vibration-controlled transient elastography (VCTE) is associated with the risk of liver decompensation in patients with non-alcoholic steatohepatitis (NASH), but prospective data in biopsy-confirmed cohorts with advanced fibrosis are limited. We aimed to establish thresholds for LS by VCTE that predict progression to cirrhosis among patients with bridging fibrosis and hepatic decompensation among patients with cirrhosis due to NASH. DESIGN: We used data from four randomised placebo-controlled trials of selonsertib and simtuzumab in participants with advanced fibrosis (F3-F4). The trials were discontinued due to lack of efficacy. Liver fibrosis was staged centrally at baseline and week 48 (selonsertib study) or week 96 (simtuzumab study). Associations between LS by VCTE with disease progression were determined using Cox proportional hazards regression analysis. RESULTS: Progression to cirrhosis occurred in 16% (103/664) of participants with bridging fibrosis and adjudicated liver-related events occurred in 4% (27/734) of participants with baseline cirrhosis. The optimal baseline LS thresholds were ≥16.6 kPa for predicting progression to cirrhosis, and ≥30.7 kPa for predicting liver-related events. Baseline LS ≥16.6 kPa (adjusted HR 3.99; 95% CI 2.66 to 5.98, p<0.0001) and a ≥5 kPa (and ≥20%) increase (adjusted HR 1.98; 95% CI 1.20 to 3.26, p=0.008) were independent predictors of progression to cirrhosis in participants with bridging fibrosis, while baseline LS ≥30.7 kPa (adjusted HR 10.13, 95% CI 4.38 to 23.41, p<0.0001) predicted liver-related events in participants with cirrhosis. CONCLUSION: The LS thresholds identified in this study may be useful for risk stratification of NASH patients with advanced fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an LSM cut-off of > -16.6 kPa (HR 3.99, 95% CI 2.6-5.98) and a > -5.5 kPa increase (and > -20%; HR 1.98, 95% CI 1.20-3.26) predicted the development of cirrhosis, whereas LSM > -30.7 kPa predicted liver-related events (HR 10.13, 4.38-23.41). 186”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [186]
Experimental — accuracy not yet measuredIn the citing paper
“Stiffness of the liver using a bedside elastography is increasingly popular for clinical care and in approximating fibrosis severity (298), but is not yet suitable as a stand-alone diagnostic for clinical trials.”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [298]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationHematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Baveno VII – Renewing consensus in portal hypertension
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.022 · Cited by 2,930
Self-citationEstes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Self-citationSampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
Ratziu, V., Charlotte, F., Heurtier, A., Gombert, S., Giral, P., Bruckert, E., Grimaldi, A., Capron, F., & Poynard, T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.03.084 · Cited by 2,106
Mechanisms and disease consequences of nonalcoholic fatty liver disease
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021) · Cell · doi:10.1016/j.cell.2021.04.015 · Cited by 2,002
Self-citationRockey, D. C., Caldwell, S. H., Goodman, Z. D., Nelson, R. C., & Smith, A. D. (2009) · Hepatology · doi:10.1002/hep.22742 · Cited by 1,997
Self-citationEstes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., Colombo, M., Craxi, A., Crespo, J., Day, C. P., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.05.036 · Cited by 1,980
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationGlobal epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Self-citation
Research works printed but not linked: 2
- Newsome, 2021, Independent validation of Agile 4: novel FibroScan based score for the diagnosis of cirrhosis in patients with non-alcoholic fatty liver disease, J Hepatol, 75, S205
- Hsieh, 2015, Correlation between noninvasive markers of fibrosis and hepatic venous pressure gradient in patients with compensated cirrhosis due to nonalcoholic steatohepatitis, Hepatology, 62, 33A
Cited by
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationKaplan, D. E., Ripoll, C., Thiele, M., Fortune, B. E., Simonetto, D. A., Garcia-Tsao, G., & Bosch, J. (2024) · Hepatology · doi:10.1097/hep.0000000000000647 · Cited by 486
Self-citationEuropean Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), & European Association for the Study of Obesity (EASO) (2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 471
Metabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
“A study of four randomized trials of participants with biopsy-proven MASH with advanced fibrosis determined that a baseline liver stiffness measurement by VCTE of ≥30.7 kPa was strongly associated with liver-related outcomes 196 .”
InfluentialSelf-citationNatural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
Metadata
- Authors
- Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., Huss, R. S., Chung, C., Goodman, Z., Wong, V. W.-S., Okanoue, T., Romero-Gómez, M., Abdelmalek, M. F., Muir, A., Afdhal, N., Bosch, J., Harrison, S., Younossi, Z. M., & Myers, R. P.
- Affiliations
- University of California San Diego (US)
- National University of Singapore (SG)
- Virginia Commonwealth University (US)
- Newcastle University (GB)
- Medical University of Vienna (AT)
- The University of Texas at San Antonio Health Science Center (US)
- Gilead Sciences (United States) (US)
- Inova Health System (US)
- Chinese University of Hong Kong (HK)
- Saiseikai Suita Hospital (JP)
- Unit for The Clinical Management of Digestive Diseases and CIBERehd, Hospital Universitario de Valme, Sevilla, Spain
- Duke University (US)
- Duke Medical Center (US)
- Harvard University (US)
- University Hospital of Bern (CH)
- University of Oxford (GB)
- Inova Fairfax Hospital (US)
- Corresponding author
- Loomba, Rohit
- ORCID
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2022-09-09
- Volume
- 72
- Issue
- 3
- Pages
- 581-589
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- PMC
- PMC9905707
- OpenAlex
- W4295074172
- Cited by
- 110
- References
- 41
- Citations by year
- 2026: 25 · 2025: 29 · 2024: 34 · 2023: 22
- FWCI
- 15.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Gut (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Gilead Sciences, Inc (NCT03053050; NCT03053063; NCT01672866; NCT01672879)
- National Center for Advancing Translational Sciences (5UL1TR001442)
- NIEHS (5P42ES010337)
- DOD PRCRP (W81XWH-18-2-0026)
- NIAAA (U01AA029019)
- National Heart, Lung, and Blood Institute (P01HL147835)
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK130190, U01DK061734, R01DK106419, P30DK120515)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Keywords
- liver stiffness, vibration-controlled transient elastography, bridging fibrosis, NASH cirrhosis, disease progression, hepatic decompensation, liver-related events, risk stratification, advanced liver fibrosis, selonsertib
- MeSH terms
- Benzamides, Humans, Imidazoles, Liver, Liver Cirrhosis, Prospective Studies, Pyridines, Retrospective Studies, Disease Progression, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. https://app.cochat.ai/papers/10.1136/gutjnl-2022-327777
- The paper
- Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., Huss, R. S., Chung, C., Goodman, Z., Wong, V. W.-S., Okanoue, T., Romero-Gómez, M., Abdelmalek, M. F., Muir, A., Afdhal, N., . . . Myers, R. P. (2023). Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis. Gut. https://doi.org/10.1136/gutjnl-2022-327777
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.